Regulation of UGT1A1 and HNF1 transcription factor gene expression by DNA methylation in colon cancer cells
Open accessThe DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
Background: UDP-glucuronosyltransferase 1A1 (UGT1A1) is a pivotal enzyme involved in metabolism of SN-38, the active metabolite of irinotecan commonly used to treat metastatic colorectal cancer. We previously demonstrated aberrant methylation of specific CpG dinucleotides in UGT1A1-negative cells, and revealed that methylation state of the UGT1A1 5'-flanking sequence is negatively correlated with gene transcription. Interestingly, one of these CpG dinucleotides (CpG -4) is found close to a HNF1 response element (HRE), known to be involved in activation of UGT1A1 gene expression, and within an upstream stimulating factor (USF) binding site. Results: Gel retardation assays revealed that methylation of CpG-4 directly affect the interaction of USF1/2 with its cognate sequence without altering the binding for HNF1-alpha. Luciferase assays sustained a role for USF1/2 and HNF1-alpha in UGT1A1 regulation in colon cancer cells. Based on the differential expression profiles of HNF1A gene in colon cell lines, we also assessed whether methylation affects its expression. In agreement with the presence of CpG islands in the HNF1A promoter, treatments of UGT1A1-negative HCT116 colon cancer cells with a DNA methyltransferase inhibitor restore HNF1A gene expression, as observed for UGT1A1. Conclusions: This study reveals that basal UGT1A1 expression in colon cells is positively regulated by HNF1-alpha and USF, and negatively regulated by DNA methylation. Besides, DNA methylation of HNF1A could also play an important role in regulating additional cellular drug metabolism and transporter pathways. This process may contribute to determine local inactivation of drugs such as the anticancer agent SN-38 by glucuronidation and define tumoral response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, UGT1A1 promoter methylation and subsequent inhibition of UGT1A1-related metabolic pathways participate in the retention of active SN-38 in CRC, enhancing the therapeutic effect of irinotecan [112].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [112]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256 · cited 1×
“Irinotecan (CPT-11) is a topoisomerase I inhibitor and one of the main cytotoxic agent for treatment of advanced metastatic colorectal cancer [1-3].”
BackgroundIrinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Saltz, L. B., Cox, J. V., Blanke, C., Rosen, L. S., Fehrenbacher, L., Moore, M. J., Maroun, J. A., Ackland, S. P., Locker, P. K., Pirotta, N., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431302 · Cited by 3,005
CpG island methylator phenotype in colorectal cancer
Toyota, M., Ahuja, N., Ohe-Toyota, M., Herman, J. G., Baylin, S. B., & Issa, J.-P. J. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.15.8681 · Cited by 2,523
Epigenetics: A landscape takes shape
Goldberg, A. D., Allis, C. D., & Bernstein, E. (2007) · Cell · doi:10.1016/j.cell.2007.02.006 · Cited by 2,466
Sawadogo, M. (1985) · Cell · doi:10.1016/0092-8674(85)90021-2 · Cited by 1,171
CpG island methylator phenotype in cancer
Issa, J.-P. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1507 · Cited by 1,098
Rougier, P., Van Cutsem, E., Bajetta, E., Niederle, N., Possinger, K., Labianca, R., Navarro, M., Morant, R., Bleiberg, H., Wils, J., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03085-2 · Cited by 992
Kawato, Y., Aonuma, M., Hirota, Y., Kuga, H., & Sato, K. (1991) · PubMed · Cited by 865
Watt, F., & Molloy, P. L. (1988) · Genes & Development · doi:10.1101/gad.2.9.1136 · Cited by 617
Methylation-Sensitive Sequence-Specific DNA Binding by the c-Myc Basic Region
Prendergast, G. C., & Ziff, E. B. (1991) · Science · doi:10.1126/science.1987636 · Cited by 579
Liver‐enriched transcription factors and hepatocyte differentiation
Cereghini, S. (1996) · The FASEB Journal · doi:10.1096/fasebj.10.2.8641560 · Cited by 510
Chodosh, L. A., Carthew, R. W., & Sharp, P. A. (1986) · Molecular and Cellular Biology · doi:10.1128/mcb.6.12.4723 · Cited by 414
Laird, P. W. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi113 · Cited by 398
Mandola, M. V., Stoehlmacher, J., Muller‐Weeks, S., Cesarone, G., Yu, M. C., Lenz, H., & Ladner, R. D. (2003) · PubMed · Cited by 362
IYER, L., HALL, D., DAS, S., MORTELL, M., RAMIREZ, J., KIM, S., DIRIENZO, A., & RATAIN, M. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(99)70078-0 · Cited by 356
Gagné, J.-F., Montminy, V., Belanger, P., Journault, K., Gaucher, G., & Guillemette, C. (2002) · Molecular Pharmacology · doi:10.1124/mol.62.3.608 · Cited by 346
Self-citationReactivating the expression of methylation silenced genes in human cancer
Karpf, A. R., & Jones, D. A. (2002) · Oncogene · doi:10.1038/sj.onc.1205602 · Cited by 264
Sawadogo, M., Van Dyke, M. W., Gregor, P. D., & Roeder, R. G. (1988) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)37883-9 · Cited by 255
Sp1 binding is inhibited by mCpmCpG methylation
Clark, S. J., Harrison, J., & Molloy, P. L. (1997) · Gene · doi:10.1016/s0378-1119(97)00164-9 · Cited by 207
Lin, Y.-M., Furukawa, Y., Tsunoda, T., Yue, C.-T., Yang, K.-C., & Nakamura, Y. (2002) · Oncogene · doi:10.1038/sj.onc.1205518 · Cited by 190
Haaz, M., Rivory, L. P., Riché, C., Vernillet, L., & Robert, J. (1998) · PubMed · Cited by 172
Sawadogo, M. (1988) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)37884-0 · Cited by 164
Hanioka, N., Ozawa, S., Jinno, H., Ando, M., Saito, Y., & Sawada, J. (2001) · Xenobiotica · doi:10.1080/00498250110057341 · Cited by 158
Houde, M., Laprise, P., Jean, D., Blais, M., Asselin, C., & Rivard, N. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100236200 · Cited by 155
Strassburg, C. P., Nguyen, N., Manns, M. P., & Tukey, R. H. (1998) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)13065-9 · Cited by 146
Regulation of UDP Glucuronosyltransferase Genes
Mackenzie, P. I., Gregory, P. A., Gardner-Stephen, D. A., Lewinsky, R., Jorgensen, B., Nishiyama, T., Xie, W., & Radominska-p, A. (2003) · Current Drug Metabolism · doi:10.2174/1389200033489442 · Cited by 143
Proteins binding to the liver-specific pyruvate kinase gene promoter
Vaulont, S., Puzenat, N., Levrat, F., Vasseur-Cognet, M., Kahn, A., & Raymondjean, M. (1989) · Journal of Molecular Biology · doi:10.1016/0022-2836(89)90273-8 · Cited by 142
Regulation of UDP glucuronosyltransferases in the gastrointestinal tract
Gregory, P. A. (2004) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2004.01.008 · Cited by 115
Paulson, K. E., Darnell, J. E., Rushmore, T., & Pickett, C. B. (1990) · Molecular and Cellular Biology · doi:10.1128/mcb.10.5.1841 · Cited by 114
Gaston, K., & Fried, M. (1995) · Nucleic Acids Research · doi:10.1093/nar/23.6.901 · Cited by 99 · cited 1×
“DNA methylation may repress transcription by sterically hindering the binding of activating transcription factors (TFs) to their recognition sites [15-17].”
BackgroundIrinotecan Inactivation Is Modulated by Epigenetic Silencing of UGT1A1 in Colon Cancer
Gagnon, J.-F., Bernard, O., Villeneuve, L., Têtu, B., & Guillemette, C. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2130 · Cited by 93
Self-citationGregory, P. A., Lewinsky, R., Gardner-Stephen, D. A., & Mackenzie, P. I. (2004) · Molecular Pharmacology · doi:10.1124/mol.65.4.953 · Cited by 81
Ishii, Y., Hansen, A. J., & Mackenzie, P. I. (2000) · PubMed · Cited by 72
Definition of the Transcriptional Activation Domain of Recombinant 43-Kilodalton USF
Kirschbaum, B. J., Pognonec, P., & Roeder, R. G. (1992) · Molecular and Cellular Biology · doi:10.1128/mcb.12.11.5094-5101.1992 · Cited by 67
Bernard, P., Goudonnet, H., Artur, Y., Desvergne, B., & Wahli, W. (1999) · Molecular Pharmacology · doi:10.1124/mol.56.3.526 · Cited by 67
Kingsley-Kallesen, M. L., Kelly, D., & Rizzino, A. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.48.34020 · Cited by 65
Enhanced clearance of topoisomerase I inhibitors from human colon cancer cells by glucuronidation
Cummings, J., Boyd, G. W., Ethell, B. T., Macpherson, J. S., Burchell, B., Smyth, J. F., & Jodrell, D. I. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(01)00812-7 · Cited by 65
Song, C. S., Jung, M. H., Kim, S. C., Hassan, T., Roy, A. K., & Chatterjee, B. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.34.21856 · Cited by 63
Gene Expression Profiling of the Irinotecan Pathway in Colorectal Cancer
Yu, J., Shannon, W. D., Watson, M. A., & McLeod, H. L. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1254 · Cited by 55
Al-Romaih, K. I., Somers, G. R., Bayani, J., Hughes, S., Prasad, M., Cutz, J., Xue, H., Zieleńska, M., Wang, Y. Z., & Squire, J. A. (2007) · Cancer Cell International · doi:10.1186/1475-2867-7-14 · Cited by 55
Ishii, Y., Hansen, A. J., & Mackenzie, P. I. (2000) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)26503-2 · Cited by 50
Umezawa, A., Yamamoto, H., Rhodes, K., Klemsz, M. J., Maki, R. A., & Oshima, R. G. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.9.4885 · Cited by 47
Szentirmay, M. N., Yang, H., Pawar, S. A., Vinson, C., & Sawadogo, M. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m305791200 · Cited by 38
Gardner-Stephen, D. A., & Mackenzie, P. I. (2007) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32801112b5 · Cited by 37
HNF-1α plays an important role in IL-6-induced expression of the human angiotensinogen gene
Jain, S., Li, Y., Patil, S., & Kumar, A. (2007) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00433.2006 · Cited by 37
Gardner-Stephen, D. A., & Mackenzie, P. I. (2008) · Current Drug Metabolism · doi:10.2174/138920008784746409 · Cited by 36
Regulation of human alcohol dehydrogenase genes
Edenberg, H. J., & Brown, C. J. (1992) · Pharmacogenetics · doi:10.1097/00008571-199210000-00001 · Cited by 33
Gardner-Stephen, D. A., & Mackenzie, P. I. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.012203 · Cited by 32
Tissue specific differences in the regulation of the UDP glucuronosyltransferase 2B17 gene promoter
Gregory, P. A., Hansen, A. J., & Mackenzie, P. I. (2000) · Pharmacogenetics · doi:10.1097/00008571-200012000-00006 · Cited by 31
Metz, R. P., Auyeung, D. J., Kessler, F. K., & Ritter, J. K. (2000) · Molecular Pharmacology · doi:10.1124/mol.58.2.319 · Cited by 29
Gardner-Stephen, D. A., Gregory, P. A., & Mackenzie, P. I. (2005) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(05)00002-9 · Cited by 19
Narvaez, M. J., Anderson, G. R., Pickwell, G. V., & Quattrochi, L. C. (2005) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.20063 · Cited by 14
Cited by
Cancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681
Cancer stem cells and chemoresistance: The smartest survives the raid
Zhao, J. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.02.008 · Cited by 437
The UDP-Glycosyltransferase (UGT) Superfamily: New Members, New Functions, and Novel Paradigms
Meech, R., Hu, D. G., McKinnon, R. A., Mubarokah, S. N., Haines, A. Z., Nair, P. C., Rowland, A., & Mackenzie, P. I. (2019) · Physiological Reviews · doi:10.1152/physrev.00058.2017 · Cited by 368
Epigenetic regulation of Keap1-Nrf2 signaling
Guo, Y., Yu, S., Zhang, C., & Kong, A.-N. T. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.06.013 · Cited by 258
Yang, X., Song, J. H., Cheng, Y., Wu, W., Bhagat, T., Yu, Y., Abraham, J. M., Ibrahim, S., Ravich, W., Roland, B. C., et al. (2014) · Gut · doi:10.1136/gutjnl-2013-305266 · Cited by 209
Metadata
- Authors
- Bélanger, A.-S., Tojcic, J., Harvey, M., & Guillemette, C.
- Affiliations
- Centre hospitalier universitaire de Québec (CA)
- Corresponding author
- Guillemette, Chantal
- ORCID
- Guillemette, Chantal
- Venue
- BMC Molecular Biology
- Published
- 2010-01-22
- Volume
- 11
- Issue
- 1
- Pages
- 9-9
- ISSN
- 1471-2199 (ISSN-L)
- PMC
- PMC2835698
- OpenAlex
- W2049537372
- Cited by
- 86
- References
- 53
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 2 · 2023: 5 · 2022: 5 · 2021: 6 · 2019: 6 · 2018: 6 · 2017: 2 · 2016: 8 · 2015: 9 · 2014: 9 · 2013: 11 · 2012: 6
- FWCI
- 2.86
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- Locations
- BMC Molecular Biology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Canadian Institutes of Health Research (MOP-42 392)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Keywords
- UGT1A1, DNA methylation, colon cancer, transcriptional regulation, CpG, hypomethylating agents, SN-38, irinotecan, glucuronidation, drug metabolism, HCT116 cells
- MeSH terms
- UGT1A1 Enzyme, Azacitidine, Base Sequence, Colonic Neoplasms, Cytidine Triphosphate, Humans, Molecular Sequence Data, Promoter Regions, Genetic, Glucuronosyltransferase, Up-Regulation, Gene Expression Regulation, Neoplastic, CpG Islands, HT29 Cells, DNA Methylation, Electrophoretic Mobility Shift Assay, HCT116 Cells, Hepatocyte Nuclear Factor 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.